FDA Approves Revolution Medicines’ Rasonque for Metastatic Pancreatic Cancer, Months Ahead of Schedule

Key Points

• The FDA approved daraxonrasib under the brand name Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
• Rasonque is an oral, once-daily RAS(ON) multi-selective inhibitor developed by Revolution Medicines.
• In the Phase 3 RASolute 302 trial, median overall survival was 13.2 months with daraxonrasib, compared with 6.7 months with standard chemotherapy.
• The study reported a 60% reduction in the risk of death versus chemotherapy, corresponding to a hazard ratio of 0.40.
• The FDA previously granted the therapy Breakthrough Therapy and Orphan Drug designations for previously treated metastatic pancreatic ductal adenocarcinoma with KRAS G12 mutations.
• The approval was reviewed under the FDA Commissioner’s National Priority Voucher pilot program and granted Priority Review, arriving roughly 6.5 months ahead of the standard user-fee deadline.
• Before approval, the FDA allowed eligible patients to receive the investigational therapy through an expanded-access treatment protocol.

The FDA has approved Revolution Medicines’ (NASDAQ: RVMD) oral RAS(ON) inhibitor daraxonrasib, which will be marketed as Rasonque, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval, granted 6.5 months ahead of the FDA’s user-fee deadline, marks a major regulatory milestone for Revolution Medicines and follows Phase 3 results showing substantially longer overall survival versus standard intravenous chemotherapy. 

Rasonque Becomes a New Oral Treatment Option for Advanced Pancreatic Cancer

Rasonque is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy, meaning the approved population includes both previously treated patients and certain chemotherapy-ineligible patients earlier in their treatment course. The medicine is taken as a pill, creating a potential alternative to intravenous cytotoxic chemotherapy for eligible patients in this difficult-to-treat cancer setting.

The approval is notable because pancreatic cancer has historically had limited effective treatment options, especially after frontline therapies stop working. Daraxonrasib is designed to inhibit active RAS proteins, an important therapeutic target because RAS mutations are found in more than 90% of pancreatic tumors.

Phase 3 Survival Results Drove FDA Review and Approval

Revolution Medicines’ Phase 3 RASolute 302 study evaluated once-daily daraxonrasib against standard-of-care intravenous chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. The company reported statistically significant and clinically meaningful improvements in both progression-free and overall survival.

Median overall survival reached 13.2 months for patients receiving daraxonrasib, compared with 6.7 months for those receiving chemotherapy. The reported overall-survival hazard ratio was 0.40, meaning the study found a 60% lower risk of death during the trial period for the daraxonrasib arm relative to the chemotherapy comparison group.

These results represent a major clinical advancement, but individual outcomes can vary. Patients should discuss eligibility, treatment benefits, risks, and alternatives with their oncology team.

FDA Designations and Expedited Review Accelerated the Regulatory Path

The FDA had already granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation for previously treated metastatic pancreatic ductal adenocarcinoma harboring KRAS G12 mutations. The agency also accepted the company’s New Drug Application for review in July 2026. Rasonque additionally received Priority Review and was evaluated under the FDA Commissioner’s National Priority Voucher pilot program, which is designed to accelerate review of therapies addressing national public health priorities. As a result, the approval arrived roughly 6.5 months ahead of the standard user-fee deadline, according to the FDA’s Oncology Center of Excellence.

Ahead of approval, the FDA authorized an expanded-access protocol that allowed eligible patients with previously treated metastatic pancreatic ductal adenocarcinoma to receive daraxonrasib in a controlled treatment setting.

What the Rasonque Approval Means for RVMD Stock

FDA approval transforms daraxonrasib from an investigational asset into Revolution Medicines’ first commercial pancreatic-cancer product. The company now faces the execution challenge of launching Rasonque, securing coverage and reimbursement, supporting patient access, and converting physician interest into sustained sales.

For RVMD investors, important milestones include the commercial launch schedule, drug pricing, payer coverage, early prescription trends, sales guidance, manufacturing capacity, label details, safety information, and expansion of daraxonrasib into other RAS-driven cancers. The approval is a landmark event, but the therapy’s long-term commercial value will depend on adoption, reimbursement, real-world outcomes, and launch execution.